Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-alcoholic Fatty Liver Disease

Author(s): Jin-Chul Kim , Joo-Yeong Jeon , Woong-suk Yang , Cheorl-Ho Kim* , Dae-Woon Eom* .

Journal Name: Current Pharmaceutical Biotechnology

Volume 20 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Red ginseng is a traditional medicine that has been used to treat numerous metabolic and inflammatory diseases. Probiotic administration has been established to have beneficial effects in non-alcoholic fatty liver disease (NAFLD). The purpose of this study was to determine whether a combination of Korean red ginseng (KRG) and probiotics could synergistically reduce NAFLD and liver inflammation compared with the effects reported for each individual product.

Method: db/db and C57BL/6 mice were fed a normal chow diet and high-fat diet (HFD), respectively, and were treated with KRG, probiotics, or both. Samples were examined for lipid content, kinase protein phosphorylation, and gene expression patterns.

Results: KRG- and probiotic-treated HFD-fed mice exhibited a reduction in body weight and a decrease in inflammatory cytokine secretion compared with the non-treated control mice. The same treatment was less successful in improving NAFLD parameters in the db/db mice while the combination of both products did not enhance their therapeutic potential.

Conclusion: The results of this study indicate that KRG and probiotics administration ameliorated NAFLD symptoms in a mouse model of dyslipidemia by reducing weight gain and liver inflammation. Coadministration of both products did not enhance their efficacy, and further research should be conducted to clarify their mechanisms of action.

Keywords: Korean Red Ginseng (KRG), liver function, Non-Alcoholic Fatty Liver Disease (NAFLD), oral administration, probiotics, blood parameters.

[1]
Almind, K.; Kahn, C.R. Genetic determinants of energy expenditure and insulin resistance in diet-induced obesity in mice. Diabetes, 2004, 53(12), 3274-3285.
[2]
Browning, J.D.; Szczepaniak, L.S.; Dobbins, R.; Nuremberg, P.; Horton, J.D.; Cohen, J.C.; Grundy, S.M.; Hobbs, H.H. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology, 2004, 40(6), 1387-1395.
[3]
Maher, J.J. New insights from rodent models of fatty liver disease. Antioxid. Redox Signal., 2011, 15(2), 535-550.
[4]
Sanders, F.W.; Griffin, J.L. De novo lipogenesis in the liver in health and disease: More than just a shunting yard for glucose. Biologic. Rev., 2016, 91(2), 452-468.
[5]
Vacca, M.; Allison, M.; Griffin, J.L.; Vidal-Puig, A. Fatty acid and glucose sensors in hepatic lipid metabolism: Implications in NAFLD. Semin. Liver Dis., 2015, 35(3), 250-261.
[6]
Wree, A.; Broderick, L.; Canbay, A.; Hoffman, H.M.; Feldstein, A.E. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol., 2013, 10(11), 627-636.
[7]
Yeh, M.M.; Brunt, E.M. Pathological features of fatty liver disease. Gastroenterology, 2014, 147(4), 754-764.
[8]
Porez, G.; Prawitt, J.; Gross, B.; Staels, B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease thematic review series: New lipid and lipoprotein targets for the treatment of cardiometabolic diseases. J. Lipid Res., 2012, 53(9), 1723-1737.
[9]
Ma, Y.Y.; Li, L.; Yu, C.H.; Shen, Z.; Chen, L.H.; Li, Y.M. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. World J. Gastroenterol., 2013, 19(40), 6911.
[10]
Malaguarnera, M.; Vacante, M.; Antic, T.; Giordano, M.; Chisari, G.; Acquaviva, R.; Mastrojeni, S.; Malaguarnera, G.; Mistretta, A.; Li Volti, G.; Galvano, F. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci., 2012, 57(2), 545-553.
[11]
Hong, S.Y.; Oh, J.H.; Lee, I. Simultaneous enrichment of deglycosylated ginsenosides and monacolin K in red ginseng by fermentation with Monascus pilosus. Biosci. Biotechnol. Biochem., 2011, 75(8), 1490-1495.
[12]
Lee, E.J.; Song, M.J.; Kwon, H.S.; Ji, G.E.; Sung, M.K. Oral administration of fermented red ginseng suppressed ovalbumin-induced allergic responses in female BALB/c mice. Phytomedicine, 2012, 19(10), 896-903.
[13]
Reeds, D.N.; Patterson, B.W.; Okunade, A.; Holloszy, J.O.; Polonsky, K.S.; Klein, S. Ginseng and ginsenoside Re do not improve β-cell function or insulin sensitivity in overweight and obese subjects with impaired glucose tolerance or diabetes. Diabetes Care, 2011, 34(5), 1071-1076.
[14]
Yang, W.S.; Lee, B.H.; Kim, S.H.; Kim, H.G.; Yi, Y.S.; Htwe, K.M.; Kim, Y.D.; Yoon, K.D.; Hong, S.; Lee, W.S.; Cho, J.Y. Dipterocarpus tuberculatus ethanol extract strongly suppresses in vitro macrophage-mediated inflammatory responses and in vivo acute gastritis. J. Ethnopharmacol., 2013, 146(3), 873-880.
[15]
Yang, Y.; Lee, J.; Rhee, M.H.; Yu, T.; Baek, K.S.; Sung, N.Y.; Kim, Y.; Yoon, K.; Kim, J.H.; Kwak, Y.S.; Hong, S.; Kim, J.H.; Cho, J.Y. Molecular mechanism of protopanaxadiol saponin fraction-mediated anti-inflammatory actions. J. Ginseng Res., 2015, 39(1), 61-68.
[16]
Park, H.M.; Kim, S.J.; Mun, A.R.; Go, H.K.; Kim, G.B. KIM, S.Z.; Jang, S.I.; Lee, S.J.; Kim, J.S.; Kang, H.S. Korean red ginseng and its primary ginsenosides inhibit ethanol-induced oxidative injury by suppression of the MAPK pathway in TIB-73 cells. J. Ethnopharmacol., 2012, 141(3), 1071-1076.
[17]
Brunt, E.M.; Janney, C.G.; Di Bisceglie, A.M.; Neuschwander-Tetri, B.A.; Bacon, B.R. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am. J. Gastroenterol., 1999, 94(9), 2467.
[18]
Ito, M.; Suzuki, J.; Tsujioka, S.; Sasaki, M.; Gomori, A.; Shirakura, T.; Hirose, H.; Ito, M.; Ishihara, A.; Iwaasa, H.; Kanatani, A. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high‐fat diet. Hepatol. Res., 2007, 37(1), 50-57.
[19]
Simon, Y.; Kessler, S.M.; Bohle, R.M.; Haybaeck, J.; Kiemer, A.K. The insulin-like growth factor 2 (IGF2) mRNA-binding protein p62/IGF2BP2-2 as a promoter of NAFLD and HCC? Gut, 2014, 63(5), 861-863.
[20]
Kouakou, K.; Schepetkin, I.A.; Yapi, A.; Kirpotina, L.N.; Jutila, M.A.; Quinn, M.T. Immunomodulatory activity of polysaccharides isolated from Alchornea cordifolia. J. Ethnopharmacol., 2013, 146(1), 232-242.
[21]
Zhao, T.; Mao, G.; Mao, R.; Zou, Y.; Zheng, D.; Feng, W.; Ren, Y.; Wang, W.; Zheng, W.; Song, J.; Chen, Y.; Yang, L.; Wu, X. Antitumor and immunomodulatory activity of a water-soluble low molecular weight polysaccharide from Schisandra chinensis (Turcz.) Baill. Food Chem. Toxicol., 2013, 55, 609-616.
[22]
Miura, K.; Kodama, Y.; Inokuchi, S.; Schnabl, B.; Aoyama, T.; Ohnishi, H.; Olefsky, J.M.; Brenner, D.A.; Seki, E. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice. Gastroenterology, 2010, 139(1), 323-334.
[23]
Nguyen, C.T.; Luong, T.T.; Lee, S.Y.; Kim, G.L.; Kwon, H.; Lee, H.G.; Park, C.K.; Rhee, D.K. Panax ginseng aqueous extract prevents pneumococcal sepsis in vivo by potentiating cell survival and diminishing inflammation. Phytomedicine, 2015, 22(11), 1055-1061.
[24]
Amin, K.A.; Kamel, H.H.; Abd Eltawab, M.A. Protective effect of Garcinia against renal oxidative stress and biomarkers induced by high fat and sucrose diet. Lipids Health Dis., 2011, 10(1), 6.
[25]
Shin, N.R.; Lee, J.C.; Lee, H.Y.; Kim, M.S.; Whon, T.W.; Lee, M.S.; Bae, J.W. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut, 2014, 63(5), 727-735.
[26]
Rawson, R.B. The SREBP pathway-insights from Insigs and insects. Nat. Rev. Mol. Cell Biol., 2003, 4(8), 631.
[27]
Wang, Y.; Viscarra, J.; Kim, S.J.; Sul, H.S. Transcriptional regulation of hepatic lipogenesis. Nat. Rev. Mol. Cell Biol., 2015, 16(11), 678.
[28]
Serviddio, G.; Bellanti, F.; Vendemiale, G. Free radical biology for medicine: Learning from nonalcoholic fatty liver disease. Free Radic. Biol. Med., 2013, 65, 952-968.
[29]
Hayakawa, R.; Hayakawa, T.; Takeda, K.; Ichijo, H. Therapeutic targets in the ASK1-dependent stress signaling pathways. Proc. Japan Acad., Series B, 2012, 88(8), 434-453.
[30]
Lawan, A.; Zhang, L.; Gatzke, F.; Min, K.; Jurczak, M.J.; Al-Mutairi, M.; Richter, P.; Camporez, J.P.; Couvillon, A.; Pesta, D.; Roth Flach, R.J.; Shulman, G.I.; Bennett, A.M. Hepatic mitogen-activated protein kinase phosphatase 1 selectively regulates glucose metabolism and energy homeostasis. Mol. Cell. Biol., 2015, 35(1), 26-40.
[31]
Bak, E.J.; Choi, K.C.; Jang, S.; Woo, G.H.; Yoon, H.G.; Na, Y.; Yoo, Y.J.; Lee, Y.; Jeong, Y.; Cha, J.H. Licochalcone F alleviates glucose tolerance and chronic inflammation in diet-induced obese mice through Akt and p38 MAPK. Clin. Nutr., 2016, 35(2), 414-421.
[32]
Sun, H.; Wang, X.; Chen, J.; Song, K.; Gusdon, A.M.; Li, L.; Bu, L.; Qu, S. Melatonin improves non-alcoholic fatty liver disease via MAPK-JNK/P38 signaling in high-fat-diet-induced obese mice. Lipids Health Dis., 2016, 15(1), 202.
[33]
Alisi, A.; Bedogni, G.; Baviera, G.; Giorgio, V.; Porro, E.; Paris, C.; Giammaria, P.; Reali, L.; Anania, F.; Nobili, V. Randomised clinical trial: The beneficial effects of VSL# 3 in obese children with non‐alcoholic steatohepatitis. Aliment. Pharmacol. Ther., 2014, 39(11), 1276-1285.
[34]
Sepideh, A.; Karim, P.; Hossein, A.; Leila, R.; Hamdollah, M.; Mohammad, E.G.; Mojtaba, S.; Mohammad, S.; Ghader, G.; Seyed Moayed, A. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: A double-blind randomized clinical trial. J. Am. Coll. Nutr., 2016, 35(6), 500-505.
[35]
Vitetta, L.; Manuel, R.; Zhou, J.Y.; Linnane, A.W.; Hall, S.; Coulson, S. The overarching influence of the gut microbiome on end-organ function: The role of live probiotic cultures. Pharmaceuticals, 2014, 7(9), 954-989.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 3
Year: 2019
Page: [222 - 231]
Pages: 10
DOI: 10.2174/1389201020666190311143554
Price: $58

Article Metrics

PDF: 35
HTML: 3